{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:38:13Z","timestamp":1790699893123,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014751","name":"Neuraxpharm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00863-2","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T02:52:46Z","timestamp":1763866366000},"page":"237-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Randomised, Double-Blind Study Comparing the Gastrointestinal Tolerability of Tegomil Fumarate Versus Dimethyl Fumarate in Healthy Volunteers"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5828-8535","authenticated-orcid":false,"given":"Marlene","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bauz\u00e0 Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkarim","family":"Bendarraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8263-7167","authenticated-orcid":false,"given":"Carmen","family":"Catal\u00e1n Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas Mohan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"10422","key":"863_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RHB, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(23)01473-3.","journal-title":"Lancet"},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"863_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","volume":"13","author":"JH Yang","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926. https:\/\/doi.org\/10.3389\/fneur.2022.824926.","journal-title":"Front Neurol"},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","volume":"80","author":"M Henderson","year":"2023","unstructured":"Henderson M, Horton DB, Bhise V, et al. Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020. JAMA Neurol. 2023;80:860\u20137.","journal-title":"JAMA Neurol"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4103\/1673-5374.320985","volume":"17","author":"E D'Amico","year":"2022","unstructured":"D\u2019Amico E, Zangh\u00ec A, Avolio C. Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies. Neural Regen Res. 2022;17:567\u20138.","journal-title":"Neural Regen Res"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12883-020-01882-2","volume":"20","author":"DM Kern","year":"2020","unstructured":"Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020;20:296.","journal-title":"BMC Neurol"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40263-014-0155-5","volume":"28","author":"CB Burness","year":"2014","unstructured":"Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014;28:373\u201387.","journal-title":"CNS Drugs"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678\u201392.","journal-title":"Brain"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087\u201397.","journal-title":"N Engl J Med"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098\u2013107.","journal-title":"N Engl J Med"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"175628641876877","DOI":"10.1177\/1756286418768775","volume":"11","author":"R Gold","year":"2018","unstructured":"Gold R, Schlegel E, Elias-Hamp B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Ther Adv Neurol Disord. 2018;11:1756286418768775.","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"863_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11101006","volume":"11","author":"PK Coyle","year":"2021","unstructured":"Coyle PK. What can we learn from sex differences in MS? J Pers Med. 2021;11(10):1006. https:\/\/doi.org\/10.3390\/jpm11101006.","journal-title":"J Pers Med"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","volume":"267","author":"J Sabin","year":"2020","unstructured":"Sabin J, Urtiaga S, Pilo B, et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol. 2020;267:2362\u201371.","journal-title":"J Neurol"},{"issue":"7","key":"863_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1185\/030079907X199637","volume":"23","author":"JM Norquist","year":"2007","unstructured":"Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007;23(7):1549\u201360. https:\/\/doi.org\/10.1185\/030079907X199637.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"863_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","volume":"18","author":"EJ Fox","year":"2016","unstructured":"Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9\u201318. https:\/\/doi.org\/10.7224\/1537-2073.2014-101.","journal-title":"Int J MS Care"},{"key":"863_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102335","volume":"45","author":"D Wynn","year":"2020","unstructured":"Wynn D, Lategan TW, Sprague TN, Rousseau FS, Fox EJ. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate. Mult Scler Relat Disord. 2020;45:102335. https:\/\/doi.org\/10.1016\/j.msard.2020.102335.","journal-title":"Mult Scler Relat Disord"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2158244014534858","volume":"4","author":"ML Bell","year":"2014","unstructured":"Bell ML, King MT, Fairclough DL. Bias in area under the curve for longitudinal clinical trials with missing patient reported outcome data: summary measures versus summary statistics. SAGE Open. 2014;4:1\u201312.","journal-title":"SAGE Open"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34:185\u201396.","journal-title":"CNS Drugs"},{"issue":"2","key":"863_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.drudis.2020.11.022","volume":"26","author":"O Findling","year":"2021","unstructured":"Findling O, Sellner J. Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? Drug Discov Today. 2021;26(2):416\u201328. https:\/\/doi.org\/10.1016\/j.drudis.2020.11.022.","journal-title":"Drug Discov Today"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","volume":"36","author":"MJ Palte","year":"2019","unstructured":"Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36:3154\u201365.","journal-title":"Adv Ther"},{"issue":"12","key":"863_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129912","volume":"24","author":"F Manai","year":"2023","unstructured":"Manai F, Zanoletti L, Arfini D, Micco SGD, Gjyzeli A, Comincini S, et al. Dimethyl fumarate and intestine: from main suspect to potential ally against gut disorders. Int J Mol Sci. 2023;24(12):9912. https:\/\/doi.org\/10.3390\/ijms24129912.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"863_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032720","volume":"24","author":"C Ferri","year":"2023","unstructured":"Ferri C, Castellazzi M, Merli N, Laudisi M, Baldin E, Baldi E, et al. Gut microbiota changes during dimethyl fumarate treatment in patients with multiple sclerosis. Int J Mol Sci. 2023;24(3):2720. https:\/\/doi.org\/10.3390\/ijms24032720.","journal-title":"Int J Mol Sci"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mib.2019.09.011","volume":"50","author":"BH Schlomann","year":"2019","unstructured":"Schlomann BH, Parthasarathy R. Timescales of gut microbiome dynamics. Curr Opin Microbiol. 2019;50:56\u201363. https:\/\/doi.org\/10.1016\/j.mib.2019.09.011.","journal-title":"Curr Opin Microbiol"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-7643-8679-5_8","volume-title":"PEGylated protein drugs: basic science and clinical applications","author":"R Webster","year":"2009","unstructured":"Webster R, Elliott V, Park BK, et al. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese FM, editor., et al., PEGylated protein drugs: basic science and clinical applications. Basel: Birkhauser; 2009. p. 127\u201348."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00863-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:59Z","timestamp":1768398719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00863-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with International Conference on Harmonisation Good Clinical Practice (ICH GCP E6 (R2)) and applicable laws and regulations. The protocol was reviewed and approved by an Independent Ethics Committee (the Portuguese Ethics Committee for Clinical Research (CEIC), Lisboa, Portugal), and all participants provided written informed consent before any procedures were undertaken.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Marlene Fonseca is an employee of BlueClinical Phase I, which was contracted by the sponsor to undertake this research. Gabriel Bauz\u00e0 Valverde, Abdelkarim Bendarraz, Carmen Catal\u00e1n Flores and Vikas Mohan Sharma are employees of the Scientific Department at Neuraxpharm.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}